| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 178.1MM | -1% |
| Gross Profit | 96.1MM | -11% |
| Cost Of Revenue | 82MM | +14% |
| Operating Income | 54MM | -26% |
| Operating Expenses | 42.2MM | +18% |
| Net Income | 36.2MM | -27% |
| R&D | 20.4MM | +23% |
| G&A | 13.1MM | +4% |
| Marketing | 8.6MM | +35% |
| Interest Expense | 9.5MM | -31% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Amphastar Pharmaceuticals, Inc. ( NASDAQ:AMPH ) shareholders might be concerned after seeing the share price drop 26...
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $41.52, representing a -1% change from its previous close.
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 1, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, and Dan Dischner SVP of Corp. Communication, will ...
The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
The latest trading day saw Amphastar Pharmaceuticals (AMPH) settling at $43.21, representing a -0.96% change from its previous close.
Amphastar Pharmaceuticals (AMPH) concluded the recent trading session at $44.03, signifying a -1.21% move from its prior day's close.
The average brokerage recommendation (ABR) for Amphastar (AMPH) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
William Peters, the Chief Financial Officer, Executive Vice President, and Treasurer of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), has sold 18,136 shares of the company on March 6, 2024, according to a recent SEC filing.
Amphastar Pharmaceuticals Inc (NASDAQ:AMPH), a company specializing in the development, manufacturing, and marketing of generic and proprietary injectable, inhalation, and intranasal products, has reported an insider sale according to a recent SEC filing.
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Barclays 26th Annual ...